Khwaja, A. and Linch, D.C. and Goldstone, A.H. and Chopra, R. and Marcus, R.E. and Wimperis, J.Z. and Russell, N.H. and Haynes, A.P. and Milligan, D.W. and Leyland, M.J. and Winfield, D.A. and Hancock, B.W. and Newland, A. and Durrant, S.T. and Devereux, S. and Roitt, S. and Collins, Michelle L. and Hudson, Gracia (1992) Recombinant Human Granulocyte Macrophage Colony-Stimulating Factor After Autologous Bone-Marrow Transplantation for Malignant-Lymphoma - A British National Lymphoma Investigation Double-Blind, Placebo-Controlled Trial. British Journal of Haematology, 82 (2). pp. 317-323. ISSN 0007-1048. (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided)
|The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. (Contact us about this Publication)|
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is active in enhancing the production of mature myeloid cells in vitro and several phase 1/11 clinical trials have suggested that its administration may accelerate neutrophil recovery after autologous bone marrow transplantation (ABMT). We have conducted a multicentre randomized double-blind placebo controlled trial in patients with poor prognosis malignant lymphoma receiving an identical high-dose combination chemotherapy regimen with ABMT. 61 patients were entered and 29 in each arm of the trial were evaluated. Treatment with GM-CSF did not affect the period of severe neutropenia (absolute neutrophil count (ANC) of < 0.1 x 10(9)/l) but accelerated recovery to an ANC of 0.5 x 10(9)/l (median 14 d v 20 d in controls, P = 0.001).There was no significant difference in platelet recovery between the groups (GM-CSF group platelet dependent for 25 d v control 19 d, P = NS). The number of positive blood cultures was similar in both groups (GM-CSF 14 v placebo 13) and there were no differences in days of fever > 37.5-degrees-C (median 8 v 6) or days on parenteral antibiotics (11 v 10). Patients receiving GM-CSF had a median period of hospitalization following BMT of 24 d (control 25). No significant major toxicity attributable to GM-CSF administration was detected. We have confirmed in a randomized trial that GM-CSF accelerates neutrophil but not platelet recovery following ABMT. We were unable to demonstrate any accompanying changes in clinical outcome and believe that further trials are necessary to assess the clinical value of GM-CSF in BMT.
|Additional information:||Received 16 March 1992; accepted for publication 28 May 1992 Correspondence: Professor D. C. Linch, Department of Haematology, University College and Middlesex School of Medicine. 98 Chenies Mews, London WClE 6HX.|
|Depositing User:||M. Nasiriavanaki|
|Date Deposited:||29 Jun 2011 12:19|
|Last Modified:||09 Jul 2014 13:19|
|Resource URI:||https://kar.kent.ac.uk/id/eprint/22328 (The current URI for this page, for reference purposes)|